Rubius Therapeutics, Inc. (RUBY)
NASDAQ: RUBY · IEX Real-Time Price · USD
0.280
+0.002 (0.68%)
Jan 27, 2023, 4:00 PM EST - Market closed
Company Description
Rubius Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of red cell therapeutics (RCTs) for the treatment of patients with severe diseases.
The company is developing RTX-240 and RTX-224 for the treatment of solid tumors cancer; and RTX-aAPC to treat cancers.
It is also developing RTX-321 for the treatment of HPV-positive tumors; and RTX-T1D for treating type 1 diabetes.
The company was incorporated in 2013 and is headquartered in Cambridge, Massachusetts.
Rubius Therapeutics, Inc.
| Country | United States |
| Founded | 2013 |
| IPO Date | Jul 18, 2018 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 9 |
| CEO | Pablo Cagnoni |
Contact Details
Address:
399 Binney Street, Suite 300 Cambridge, Massachusetts 02139 United States | |
| Phone | 617-679-9600 |
| Website | rubiustx.com |
Stock Details
| Ticker Symbol | RUBY |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001709401 |
| CUSIP Number | 78116T103 |
| ISIN Number | US78116T1034 |
| Employer ID | 04-2688109 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dannielle Appelhans | Chief Executive Officer and Pres |
| Jose I. Carmona M.B.A. | Principal Accounting Officer and Treasurer |
| Dr. Laurence A. Turka M.D. | Chief Scientific Officer and Head of Research and Translational Medicine |
| Marissa Hanify | Director of Corporate Communications |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jan 20, 2023 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Dec 21, 2022 | 8-K | Current Report |
| Dec 14, 2022 | 8-K | Current Report |
| Dec 12, 2022 | 8-K | Current Report |
| Nov 9, 2022 | 10-Q | Quarterly Report |
| Nov 2, 2022 | 8-K | Current Report |
| Oct 17, 2022 | 8-K | Current Report |
| Oct 13, 2022 | 8-K | Current Report |
| Sep 13, 2022 | 8-K | Current Report |
| Aug 12, 2022 | 8-K | Current Report |